R
Since its launch in June, the usage of Gilead Sciences' Yeztugo, a twice-yearly injection for HIV prevention, has increased, but many patients face challenges such as insurance coverage gaps and a preference for daily pills over the injectable option. #HIVPrevention #PrEP #HealthcareAccess #US
www.reuters.com
Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain
May 5 (Reuters) - Use of Gilead Sciences' (GILD. O), opens new tab Yeztugo, a twice-yearly injection to prevent HIV infection, has climbed since its June launch, but U.